Community Medicine

Community Medicine — also called Preventive and Social Medicine (PSM) or Social and Preventive Medicine (SPM) — is the highest-yield-per-hour subject in the entire NEET PG and INI-CET syllabus. It is the subject where a focused candidate can convert raw, factual recall into the maximum number of guaranteed marks, because it rewards memory of values, year-cuts, definitions and programme details rather than complex clinical reasoning. The flip side is that it is a vast, dry, number-heavy subject where students drown unless they study it the way it is tested — by high-yield clusters — rather than reading Park cover to cover.

This mother page maps the subject the way examiners attack it, group by group, with the must-know values, classic associations, recurring traps, cross-subject overlaps, recent guideline shifts (NFHS-5, updated programme nomenclature, revised vaccine schedules), a study roadmap, and a rapid-fire revision battery at the end.

---

How Community Medicine Is Tested

Weightage and exam pattern

Exam	Approx. questions	Share	Character of questions
NEET PG	12–17 / 200	~6–8%	Single-best-answer; heavily factual, value-based
INI-CET (AIIMS/JIPMER)	8–14 / 200	~5–7%	More applied — formulas, study-design logic, ethics
FMGE	12–15 / 300	~4–5%	Direct factual, programme-heavy

Despite being only ~6–8% of the paper, PSM punches above its weight because the questions are answerable in under 30 seconds and have a low ambiguity rate. A clinical subject question can be debated; "What is the incubation period of measles?" cannot. This is the subject that protects your rank in the last 20 minutes of the exam.

Recurring question styles

• Direct value recall — "Permissible limit of fluoride in drinking water?" (1.0 mg/L; max 1.5).
• Match the association — vaccine to vaccine type, disease to vector, study to bias.
• Calculation — sensitivity/specificity, attributable risk, standardised mortality ratio, sample-size logic.
• Study-design identification — a clinical vignette describing a cohort/case-control/cross-sectional design and asking the appropriate measure of association.
• National programme details — eligibility, dose, cut-offs, year of launch, target.
• "Which is the best/most appropriate" reasoning — screening test choice, sampling method, disinfectant.
• Image/graph-based (rising in INI-CET) — epidemic curve shapes, survival curves, types of graphs.

The cardinal rule

Examiners love numbers, cut-offs, and "firsts." First eradicated disease (smallpox), first disease targeted for elimination, lowest/highest values, exact incubation periods, exact vaccine doses. Build a "numbers sheet" early — it is the single most cost-effective revision asset in the subject.

---

Epidemiology

Epidemiology is the conceptual spine of the subject and the most consistently tested group. Master measures of frequency, measures of association, study designs, and screening — these four buckets alone yield the majority of epidemiology marks.

Must-know measures of frequency

• Incidence = new cases / population at risk over a period (measures risk/force of morbidity).
• Prevalence = all existing cases / total population at a point (or period).
• Relationship: Prevalence ≈ Incidence × Duration (P = I × D). A chronic disease with long duration (e.g., diabetes) has high prevalence even with modest incidence. A short fatal disease has low prevalence.
• Attack rate = incidence in an epidemic (used for acute outbreaks; expressed as %).
• Secondary attack rate = new cases among contacts / total susceptible contacts — measures infectivity.

Study designs — the most tested table

Design	Direction	Measures	Strength	Classic trap
Cross-sectional	At one point	Prevalence	Quick, cheap	Cannot establish temporality/causation
Case-control	Backward (effect→cause)	Odds Ratio	Good for rare diseases, cheap, fast	Recall & selection bias; cannot give incidence
Cohort	Forward (cause→effect)	Relative Risk, Incidence, Attributable Risk	Establishes temporality, good for rare exposures	Expensive, long, loss to follow-up; bad for rare diseases
RCT	Forward, randomised	RR, efficacy	Best evidence, removes confounding	Costly, ethical limits

Hierarchy of evidence (high→low): Meta-analysis/Systematic review > RCT > Cohort > Case-control > Cross-sectional > Case series/report > Expert opinion.

Measures of association (commit to memory)

• Relative Risk (RR) = Incidence in exposed / Incidence in unexposed (cohort). RR=1 no association; >1 risk factor; <1 protective.
• Odds Ratio (OR) = ad/bc (case-control). Approximates RR when disease is rare.
• Attributable Risk (AR) = Incidenceexposed − Incidenceunexposed (absolute excess risk due to exposure).
• Population Attributable Risk (PAR) — informs public-health priority.
• Number Needed to Treat (NNT) = 1 / Absolute Risk Reduction.

Screening — sensitivity & specificity

Term	Formula	Memory hook
Sensitivity	TP / (TP+FN)	PID — Positive In Disease; rules out (SnNout)
Specificity	TN / (TN+FP)	NIH — Negative In Health; rules in (SpPin)
PPV	TP / (TP+FP)	Rises with prevalence
NPV	TN / (TN+FN)	Falls with prevalence

• Sensitivity & specificity are intrinsic to the test (independent of prevalence). PPV/NPV depend on prevalence.
• For a screening programme of a serious treatable disease, prioritise sensitivity (don't miss cases). For confirmation, prioritise specificity.
• Sequential (two-step) testing raises specificity; simultaneous (parallel) testing raises sensitivity.
• Lead-time bias and length-time bias classically inflate apparent survival in screening — high-yield trap.

Epidemics and types of association

• Epidemic curve shapes: single sharp peak = point-source (common-source single-exposure); plateau/multiple peaks = propagated/person-to-person.
• Bradford Hill criteria for causation: strength, consistency, temporality (the only essential one), biological gradient (dose-response), plausibility, specificity, coherence, experiment, analogy.
• Bias vs confounding vs chance — confounding is associated with both exposure and outcome and is not in the causal pathway; controlled by randomisation, matching, restriction, stratification, multivariable analysis.

Traps: confusing OR with RR; assuming case-control gives incidence; forgetting that PPV depends on prevalence; mislabeling the only essential Bradford Hill criterion (temporality).

---

Biostatistics

Biostatistics is short but disproportionately rewarding in INI-CET. Focus on data types, central tendency/dispersion, normal distribution, sampling, and significance testing.

Data types and appropriate tests

Data type	Example	Central tendency	Graph
Nominal (qualitative)	Blood group	Mode	Bar / pie
Ordinal	Pain scale	Median	Bar
Discrete quantitative	No. of children	Mean/median	Bar/histogram
Continuous quantitative	Height, BP	Mean	Histogram, frequency polygon

Normal (Gaussian) distribution

• Bell-shaped, symmetrical; mean = median = mode.
• 68–95–99.7 rule: ±1 SD = 68.2%, ±2 SD = 95.4%, ±3 SD = 99.7%.
• For a "normal range," mean ± 1.96 SD covers 95%.
• Standard error of mean (SEM) = SD / √n — decreases as sample size rises.
• Skewed data → use median; mean is pulled toward the tail.

Significance testing

Situation	Test
Compare two means (quantitative, normal)	Student's t-test (unpaired) / paired t-test
Compare >2 means	ANOVA
Compare proportions / categorical data	Chi-square test
Small sample categorical	Fisher's exact test
Non-parametric (skewed) two groups	Mann-Whitney U / Wilcoxon
Correlation of two continuous variables	Pearson's r (−1 to +1)

• p < 0.05 = statistically significant (5% chance result is due to chance).
• Type I error (α) = rejecting a true null (false positive). Type II error (β) = accepting a false null (false negative). Power = 1 − β.
• Confidence interval crossing 1 (for RR/OR) or 0 (for difference) = not significant.

Traps: choosing the wrong test (t-test for categorical data); confusing SD with SEM; mislabeling Type I vs II error; forgetting that increasing sample size raises power and narrows CI.

---

Nutrition

Nutrition is dense with values, deficiency syndromes, and assessment indices — all favourites of examiners.

Energy, proteins and reference values

• Reference Indian adult man (sedentary): ~2110–2320 kcal/day (ICMR-NIN 2020 revised); woman lower.
• Protein requirement: ~0.8–1 g/kg/day; safe intake ~1 g/kg.
• Reference protein (highest biological value): Egg (NPU & BV reference). Breast milk and egg are the gold standards.
• Limiting amino acid in cereals = lysine; in pulses = methionine (hence cereal-pulse combination is complementary).

Vitamin deficiency one-liners

Deficiency	Disease / sign
Vitamin A	Night blindness, Bitot's spots, xerophthalmia, keratomalacia
Vitamin D	Rickets (child), osteomalacia (adult)
Vitamin B1 (thiamine)	Beri-beri, Wernicke-Korsakoff
Vitamin B3 (niacin)	Pellagra (3 Ds — dermatitis, diarrhoea, dementia)
Vitamin C	Scurvy
Iodine	Goitre, cretinism
Iron	Microcytic anaemia

Nutritional assessment — classifications

• IAP classification of PEM uses % of expected weight-for-age.
• Gomez classification: weight-for-age (I = 75–90%, II = 60–75%, III = <60%).
• Waterlow: stunting (height-for-age, chronic) vs wasting (weight-for-height, acute).
• WHO MUAC (mid-upper arm circumference): **<11.5 cm = severe acute malnutrition (SAM)** in 6–59 months; 11.5–12.5 cm = moderate. (1–5 yr MUAC normally >13.5 cm.)
• BMI: <18.5 underweight, 18.5–22.9 normal (Asian), 23–24.9 overweight, ≥25 obese (Asian/Indian cut-offs are lower than WHO global).

National nutrition values and fortification

• Vitamin A prophylaxis: 1 lakh IU at 9 months with measles, then 2 lakh IU every 6 months up to 5 years (total 9 megadoses).
• Salt iodisation: ≥15 ppm at consumer level (≥30 ppm at production).
• Fluoride in water: optimal 0.5–0.8 mg/L (India); >1.5 mg/L → fluorosis; <0.5 → caries.

Traps: mixing up Gomez (weight-for-age) with Waterlow (stunting/wasting); confusing SAM MUAC cut-off (<11.5 cm); using global BMI cut-offs instead of Asian; misremembering vitamin A megadose schedule.

---

Communicable Disease

The largest factual block — incubation periods, vaccines, vector-disease pairs, and disinfection. Build dedicated charts.

Incubation periods (high-yield)

Disease	Incubation period
Cholera	Few hours–5 days
Measles	~10 days (to fever), 14 to rash
Chickenpox	14–16 days
Mumps	18 days
Rubella	14–21 days
Diphtheria	2–5 days
Pertussis	7–14 days
Polio	7–14 days
Rabies	1–3 months (variable, weeks–years)
Tetanus	6–10 days
Hepatitis A	15–45 days
Hepatitis B	30–180 days

Vector–disease associations

Vector	Diseases
Anopheles	Malaria
Aedes	Dengue, chikungunya, yellow fever, Zika
Culex	Japanese encephalitis, filariasis, West Nile
Sandfly (Phlebotomus)	Kala-azar (visceral leishmaniasis), sandfly fever
Tsetse fly	African trypanosomiasis (sleeping sickness)
Rat flea (Xenopsylla)	Plague, endemic typhus
Hard tick	KFD, Lyme, Rocky Mountain spotted fever
Louse	Epidemic typhus, relapsing fever, trench fever

Disinfection and sterilisation

• Autoclaving (moist heat, 121°C/15 psi/15 min) — most reliable sterilisation.
• Bleaching powder (chlorine) — water disinfection; chlorine demand must be met first; free residual chlorine 0.5 mg/L after 1 h contact. Orthotolidine test measures residual chlorine.
• Horrock's apparatus — estimates dose of bleaching powder for well disinfection.
• Cobalt-60 gamma irradiation — sterilising disposables.

Eradication, elimination, control milestones

• Smallpox — only disease eradicated (India 1977, world 1980; last natural case Rahima Banu/Ali Maow Maalin).
• Polio — India certified polio-free 2014; switched to bivalent OPV + IPV.
• Guinea worm (dracunculiasis) — eliminated from India 2000; near global eradication.
• Yaws — India first country certified yaws-free (2016).
• Maternal & neonatal tetanus — India eliminated 2015.

Immunisation — the National Immunization Schedule (NIS)

Age	Vaccines
Birth	BCG, OPV-0, Hepatitis B birth dose
6 weeks	OPV-1, Pentavalent-1, RVV-1, fIPV-1, PCV-1
10 weeks	OPV-2, Pentavalent-2, RVV-2
14 weeks	OPV-3, Pentavalent-3, RVV-3, fIPV-2, PCV-2
9–12 months	MR-1, JE-1, PCV-booster, Vitamin A
16–24 months	DPT-booster-1, OPV-booster, MR-2, JE-2
5–6 years	DPT-booster-2
10 & 16 years	Td
Pregnancy	Td-1, Td-2 (or Td-booster)

• Pentavalent = DPT + Hep B + Hib.
• Live vaccines: BCG, OPV, measles/MR, rotavirus, yellow fever, varicella, typhoid oral — contraindicated in pregnancy & immunocompromised.
• Cold chain: OPV most heat-sensitive (kept in deep freeze); diluents never frozen; vaccines damaged by freezing — DPT, Hep B, TT, IPV (the "freeze-sensitive" group).

Traps: placing rotavirus/PCV at wrong visits; confusing pentavalent constituents; forgetting fIPV (fractional IPV) is now intradermal at 6 & 14 weeks; mixing live vs killed vaccine lists; thinking all vaccines must be frozen (freeze-sensitive ones are destroyed by freezing).

---

Non-communicable Disease

NCDs now dominate India's disease burden, and examiners reflect this with questions on risk factors, screening cut-offs, and tobacco/cancer epidemiology.

Key concepts and cut-offs

• Leading cause of death in India has shifted from communicable to cardiovascular disease (NCDs now ~60%+ of deaths).
• Hypertension: ≥140/90 mmHg (JNC); population-based screening under NP-NCD from age 30.
• Diabetes screening: FBS ≥126, RBS/2-h ≥200, HbA1c ≥6.5%.
• Obesity (Asian): BMI ≥25; central obesity waist >90 cm (men), >80 cm (women).
• Cancer screening (India, NP-NCD): oral, breast, cervical from age 30; cervical via VIA (visual inspection with acetic acid) — the chosen low-cost screening method in India.

Tobacco and cancer

• Tobacco is the leading preventable cause of death; oral cancer is the commonest cancer in Indian men (cervical historically commonest in women, now breast leading in urban women).
• COTPA 2003 — Cigarettes and Other Tobacco Products Act (advertising ban, no sale to minors, smoke-free public places).
• Levels of prevention: primordial (risk-factor prevention in whole population) → primary (specific protection/health promotion) → secondary (early diagnosis/screening) → tertiary (disability limitation & rehabilitation).

Traps: confusing primordial vs primary prevention; using global obesity cut-offs; forgetting VIA as India's cervical screening method; mixing screening age cut-offs.

---

National Health Programmes

The single most exam-dense block. Programmes change names and targets, so prioritise current nomenclature, eligibility, and dose/cut-off details.

High-yield programmes

Programme	Key facts
NTEP (ex-RNTCP)	National TB Elimination Programme; target TB elimination by 2025 (ahead of SDG 2030). Daily regimen, fixed-dose combos, Ni-kshay portal, Nikshay Poshan Yojana ₹1000/month (revised) nutrition support, NAAT/CBNAAT (GeneXpert) as initial diagnostic.
NVBDCP	Vector-borne: malaria, filaria, kala-azar, dengue, JE, chikungunya. Malaria elimination target 2030.
NLEP	Leprosy; MDT; elimination (<1/10,000) achieved 2005; aiming zero transmission.
NACP	HIV/AIDS; NACO; "Treat All" — ART for all PLHIV; 95-95-95 targets.
RMNCH+A / RCH	Reproductive, Maternal, Newborn, Child, Adolescent + A (RKSK for adolescents).
JSY / JSSK	Janani Suraksha Yojana (cash for institutional delivery); JSSK (free delivery, drugs, transport, C-section).
POSHAN Abhiyaan	Nutrition mission; targets stunting, anaemia, low birth weight.
Anaemia Mukt Bharat	6×6×6 strategy; IFA prophylaxis across life stages.
Mission Indradhanush / IMI	Full immunisation coverage drive; Intensified MI 5.0.
NP-NCD (ex-NPCDCS)	National Programme for NCDs; population-based screening ≥30 yr.
Ayushman Bharat	HWCs (Health & Wellness Centres) + PM-JAY (₹5 lakh/family/year hospitalisation cover).

Maternal & child health indicators (NFHS-5, 2019–21)

Indicator	NFHS-5 value (trend)
TFR (Total Fertility Rate)	2.0 (below replacement 2.1)
IMR (Infant Mortality Rate)	~35/1000 live births
U5MR	~42/1000
Sex ratio (total)	1020 females/1000 males (first time >1000)
Institutional deliveries	~89%
Full immunisation (12–23 mo)	~76%
Children stunted (<5 yr)	~35.5%
Anaemia in women (15–49)	~57% (rose vs NFHS-4)
MMR (SRS, not NFHS)	97/100,000 live births

Traps: using outdated RNTCP/NPCDCS names; misremembering Ayushman Bharat cover (₹5 lakh) or PM-JAY vs HWC split; confusing JSY (cash incentive) with JSSK (free entitlements); mixing NFHS-5 sex ratio (1020) with child sex ratio; forgetting MMR comes from SRS, not NFHS.

---

Demography

Demography ties together population dynamics, vital statistics, family planning, and the demographic cycle.

Demographic cycle and India's stage

• Stages: high stationary → early expanding → late expanding → low stationary → declining.
• India is in the late expanding stage (declining birth rate, low death rate) and approaching low stationary, with TFR now at replacement.
• Demographic dividend — large working-age population; India's window to ~2040s.

Vital statistics and fertility indicators

Indicator	Definition
Crude Birth Rate (CBR)	Live births / mid-year population × 1000
Crude Death Rate (CDR)	Deaths / mid-year population × 1000
General Fertility Rate (GFR)	Live births / women 15–49 × 1000
Total Fertility Rate (TFR)	Avg children per woman over reproductive life; replacement = 2.1
Net Reproduction Rate (NRR)	Daughters replacing mothers; NRR = 1 is the goal (replacement)
Dependency ratio	(0–14 + 65+) / 15–64

Family planning

• Most effective spacing method: IUCD / hormonal implants; most effective overall: sterilisation.
• Most popular method in India: female sterilisation (tubectomy).
• Pearl Index = failure rate per 100 woman-years (lower = more effective).
• Couple Protection Rate (CPR) — % eligible couples using contraception; ~60% target.
• Eligible couple — married, wife 15–45 yrs.

Census and sources

• Census — every 10 years (de facto); last completed 1872 first, 2011 latest decennial.
• SRS (Sample Registration System) — source of IMR, MMR, CBR, CDR.
• NFHS — large-scale household survey (NFHS-5 is latest); does not give MMR.

Traps: confusing NRR=1 (replacement) with TFR=2.1; mixing GFR vs TFR; attributing MMR to NFHS (it comes from SRS); calling India "low stationary" (it's late expanding).

---

Cross-Subject Integration & Overlaps

Community Medicine is a connective subject — its facts resurface across the paper:

• Microbiology overlap: vaccine types (live/killed/toxoid/subunit), incubation periods, disinfection/sterilisation, vector biology, notifiable diseases.
• Pharmacology overlap: NTEP drug regimens (RIPE), MDT for leprosy, ART, pharmacovigilance, essential drug list, randomised trial design.
• Medicine overlap: NCD screening cut-offs (HTN, DM, dyslipidemia), TB diagnosis, dengue/malaria management aligning with programme guidelines.
• OBG/Paediatrics overlap: NIS schedule, IMNCI, maternal mortality, contraception, ANC under RCH, growth charts, SAM/MAM management.
• Forensic Medicine overlap: vital statistics registration, medical ethics, consent, MTP Act, notifiable deaths.
• Ethics & research methodology (INI-CET favourite): informed consent, Declaration of Helsinki, ethical principles (autonomy, beneficence, non-maleficence, justice), confounding/bias — frequently bridged with biostatistics.

A question framed as "Medicine" (e.g., HbA1c cut-off) or "Microbiology" (vaccine type) is often really a PSM question. Treat PSM as the glue subject and you gain marks elsewhere too.

---

Recent Update Themes (current-exam relevant)

• NFHS-5 (2019–21) is now the default data source: TFR 2.0 (below replacement), total sex ratio 1020, rising anaemia prevalence. Expect direct-value questions.
• Programme renaming: RNTCP → NTEP; NPCDCS → NP-NCD. Always pick the current name in MCQs.
• TB elimination target 2025 (India's accelerated goal vs global SDG 2030); Ni-kshay Poshan revised support.
• Updated immunisation: fIPV (fractional IPV) intradermal at 6 & 14 weeks, PCV nationwide rollout, rotavirus universal.
• Ayushman Bharat maturation: HWCs renamed Ayushman Arogya Mandir; PM-JAY ₹5 lakh cover; expansion to 70+ age group.
• ICMR-NIN 2020 RDA revision — updated energy/protein reference values (lower than older ICMR 2010 figures).
• Eliminations/firsts: India's progress on kala-azar elimination, lymphatic filariasis MDA, measles-rubella elimination push.
• Digital health: Ayushman Bharat Digital Mission (ABHA ID), eVIN (electronic Vaccine Intelligence Network) for cold-chain.

---

Study Roadmap

Phase 1 — Foundation (4–6 weeks, alongside other subjects)

• Read epidemiology + biostatistics conceptually once (Park or a crisp PSM notes module). These are understanding topics — don't merely memorise.
• Build three master sheets: Numbers/values, National programmes, Immunisation & vaccines.

Phase 2 — Consolidation (3–4 weeks)

• Memorise programme details, NFHS-5 indicators, incubation periods, vector pairs, vitamin deficiencies.
• Solve topic-wise PYQs after each group — PSM PYQs repeat heavily; the same values reappear across years.

Phase 3 — Application (2 weeks)

• Drill calculation questions (sensitivity/specificity, RR/OR, AR, SMR) and study-design vignettes for INI-CET.
• Take subject-wise grand tests; review every wrong value and add it to the numbers sheet.

Last-week revision strategy

• Revise only your three master sheets + the rapid-fire one-liners — do not open Park.
• Re-read NIS schedule, NFHS-5 values, current programme names, and the top 30 incubation periods/cut-offs the night before.
• PSM is the subject to revise last before sleep and first in the morning — it is pure recall and decays fast.
• In the exam, answer PSM questions early to bank quick, certain marks and build momentum.

---

High-Yield Mnemonics

• SnNout / SpPin — a Snensitive test when Negative rules out; a Specific test when Positive rules in.
• PID / NIH — sensitivity = Positive In Disease; specificity = Negative In Health.
• Live vaccines — "My Bovine Yak Of Rare Value" = Measles/MMR, BCG, Yellow fever, OPV, Rotavirus, Varicella (live attenuated).
• Pellagra 3 Ds — Dermatitis, Diarrhoea, Dementia (niacin/B3).
• Bradford Hill — only temporality is essential for causation.
• Pentavalent — "DH-Hib" = DPT + Hep B + Hib.

---

Rapid-Fire One-Liners

1. Only disease eradicated worldwide — smallpox (1980); India became smallpox-free 1977.
2. Replacement-level fertility = TFR 2.1; NRR = 1. India's NFHS-5 TFR is 2.0.
3. MUAC <11.5 cm (6–59 months) = severe acute malnutrition (SAM).
4. P = I × D (prevalence = incidence × duration).
5. Case-control study measures Odds Ratio; cohort measures Relative Risk & incidence.
6. Free residual chlorine after water disinfection should be 0.5 mg/L after 1-hour contact.
7. Reference protein with highest biological value = egg.
8. Most popular contraceptive method in India = female sterilisation (tubectomy).
9. Pearl Index = contraceptive failures per 100 woman-years.
10. NFHS-5 total sex ratio = 1020 females per 1000 males (first time above 1000).
11. India's TB elimination target = 2025 (programme: NTEP, portal: Ni-kshay).
12. Type I error (α) = false positive (reject true null); Power = 1 − β.
13. Vitamin A: 1 lakh IU at 9 months, then 2 lakh IU 6-monthly to 5 years (9 megadoses total).
14. MMR (India, SRS) ≈ 97/1,00,000 live births; MMR is not from NFHS.